Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results

RESEARCH TRIANGLE PARK, N.C., July 16 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) will issue its second quarter 2010 earnings release before the market opens on July 29, 2010. Due to the pending merger with Grifols, S.A., Talecris will not be hosting a conference call to discuss its second quarter results.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.

SOURCE Talecris Biotherapeutics Holdings Corp.

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.